CDV Specific Neutra™ Antibody Products

Are you struggling with prolonged antiviral drug development or inconsistent neutralizing antibody efficacy against canine distemper virus (CDV)? Creative Biolabs' CDV specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver high-affinity, cross-reactive antibodies that enhance therapeutic potency and streamline preclinical validation.

Introduction to CDV

Canine distemper virus (CDV), a member of the Paramyxoviridae family and genus Morbillivirus, is an enveloped, single-stranded RNA virus with a genome encoding six structural proteins. CDV exhibits broad host tropism, infecting domestic dogs, wild carnivores (e.g., foxes, wolves), and even non-human primates. Its high mutation rate and environmental persistence contribute to recurrent outbreaks, posing significant challenges to veterinary and wildlife conservation efforts.

• Structural Features

The virion comprises a lipid envelope studded with hemagglutinin (H) and fusion (F) glycoproteins, which mediate host cell entry. The H protein binds to host receptors (e.g., signaling lymphocyte activation molecule, SLAM), while the F protein facilitates membrane fusion. The nucleocapsid core contains the RNA genome coiled with nucleoprotein (N), polymerase (L), and phosphoprotein (P), critical for replication. Cryo-EM studies reveal conformational flexibility in the H protein, enabling immune evasion and adaptation to diverse hosts.

Fig.1 CDV virion and genome organization.¹

• Host Signaling Pathways

CDV infection disrupts interferon (IFN) signaling by degrading STAT1/STAT2 via viral V and C proteins, suppressing innate immunity. Concurrently, the virus activates NF-κB pathways to promote viral transcription while inducing apoptosis in lymphocytes, leading to immunosuppression. These dual mechanisms enable systemic spread and secondary infections, complicating disease management.

Fig.2 Principle routes of CDV infection and transmission in hosts.¹

• Associated Pathologies

CDV causes multisystemic disease characterized by biphasic fever, respiratory distress, neurological deficits (e.g., seizures), and hyperkeratosis. Mortality rates exceed 50% in unvaccinated populations, with survivors often suffering lifelong neurological sequelae. The virus also drives population declines in endangered wildlife, underscoring its ecological and economic impact.

Applications of Anti-CDV Neutralizing Antibodies

• Therapeutic Development

Anti-CDV antibodies are pivotal in post-exposure prophylaxis and acute-phase treatment. Administered intravenously, they reduce viral load in cerebrospinal fluid and lung tissue, mitigating neurological damage and respiratory failure. Clinical trials in wildlife reservoirs demonstrate a 70% survival rate increase when antibodies are delivered early.

• Diagnostic Tool Innovation

High-specificity anti-CDV antibodies enable rapid antigen detection in serum or nasal swabs using lateral flow assays. They also improve immunohistochemical (IHC) staining accuracy for post-mortem confirmation in field settings, aiding outbreak surveillance.

• Vaccine Efficacy Evaluation

These antibodies serve as positive controls in virus neutralization tests (VNTs) to quantify vaccine-induced immunity. By correlating antibody titers with protection thresholds, researchers optimize vaccination schedules and adjuvant formulations.

Our Anti-CDV Neutralizing Antibodies

Creative Biolabs' anti-CDV antibodies target the H protein's receptor-binding domain (RBD), blocking viral attachment and entry. Engineered for cross-reactivity against circulating strains (e.g., Asia-1, Europe), these antibodies exhibit >90% neutralization efficacy in vitro. Rigorously validated in ELISA, pseudovirus assays, and animal models, they are ideal for therapeutic development and diagnostic tool optimization. Key advantages include:

- High batch-to-batch consistency.

- Low cross-reactivity with host proteins.

- Customizable formats (IgG1/IgG2a) for tailored therapeutic strategies.

Creative Biolabs provides CDV specific Neutra™ antibody products with unmatched precision for advancing canine distemper therapeutics, diagnostics, and vaccines. Our team combines decades of virology expertise with cutting-edge antibody engineering to deliver solutions tailored to your project's needs. Contact us today to discuss your CDV research goals.

REFERENCE

1. Rendon-Marin, Santiago, et al. "Tropism and molecular pathogenesis of canine distemper virus." Virology journal 16.1 (2019): 30. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12985-019-1136-6